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 Network-based method for inferring cancer 
progression at the pathway level from 
cross-sectional mutation data 
Hao Wu, Lin Gao, Nikola Kasabov 
Abstract—Large-scale cancer genomics projects are providing a wealth of somatic mutation data from a large number of cancer 
patients. However, it is difficult to obtain several samples with a temporal order from one patient in evaluating the cancer 
progression. Therefore, one of the most challenging problems arising from the data is to infer the temporal order of mutations 
across many patients. To solve the problem efficiently, we present a Network-based method (NetInf) to Infer cancer progression at 
the pathway level from cross-sectional data across many patients, leveraging on the exclusive property of driver mutations within a 
pathway and the property of linear progression between pathways. To assess the robustness of NetInf, we apply it on simulated 
data with the addition of different levels of noise. To verify the performance of NetInf, we apply it to analyze somatic mutation data 
from three real cancer studies with large number of samples. Experimental results reveal that the pathways detected by NetInf 
show significant enrichment. Our method reduces computational complexity by constructing gene networks without assigning the 
number of pathways, which also provides new insights on the temporal order of somatic mutations at the pathway level rather than 
at the gene level. 
Index Terms—Cancer genome, cancer progression, driver mutation, driver pathways, complex network 
 
——————————      —————————— 
 
1 INTRODUCTION 
ancer has become one of the most serious threats to 
human health. Cancer is driven mainly by somatic 
mutations, including small indels, large copy number 
aberrations, single nucleotide substitution, and structural 
aberrations that accumulate during the lifetime of an 
individual [1], [2], [3]. A large number of somatic 
mutations have been already identified in the genomes. In 
recent years, high-throughput DNA sequencing 
technologies are measuring somatic mutations in many 
cancer genomes as part of large projects, such as 
International Cancer Genome Consortium (ICGC) [4], The 
Cancer Genome Atlas (TCGA) [5] and so on. According to 
the analysis of somatic mutations in cancer genomes, three 
important problems appear. First, how to distinguish 
driver mutations, which contribute to tumorigenesis, from 
passenger mutations, which are merely random, 
functionally neutral and have no consequence for cancer 
[6], [7], [8], [9], [10], [11]. Second, how to detect driver 
pathways, which are frequently perturbed with a large 
number of tumor cells, and give rise to the product of 
tumorigenic properties, such as cell angiogenesis, 
proliferation or metastasis [1], [2], [3], [12], [13], [14], [15], 
[16], [17]. Third, how to determine temporal orders of the 
driver mutations in cancer patients [18], [19], [20], [21], 
[22]. The first question can usually be solved by 
comparing mutation frequencies across different 
individuals [6], [7], [8], [9], [10], [11]. Several methods 
have been developed to address the second question, 
based on two properties - high coverage and high 
exclusivity of the driver pathways [1], [2], [3], [13], [16].  
However, it is almost impossible to obtain samples at 
multiple time-points from a single individual, therefore, it 
is difficult to answer the question about temporal 
progression and identify what mutations occur early in 
cancer progression [18], [19], [20], [21], [22]. One 
systematic approach to address the task is to identify 
mutually exclusive gene sets in cancer genomic data [1], 
[2], [3], [12], [13], [14], [15], [16], [23]. In mutually exclusive 
patterns, the mutations tend to occur in different patients. 
Such mutually exclusive gene sets have been identified in 
cancer data and found to be associated with synthetic 
lethality or functional pathways [2], [3], [12], [13]. 
Therefore, it is important to identify the mutually 
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exclusive patterns for a basic understanding of cancer 
progression and targeted treatment [23]. Taking into 
account cancer phylogeny, we aim at identifying the 
mutually exclusive gene sets in the process of cancer 
progression that can help us develop new diagnostics or 
therapeutics targeted to specific subtypes of progression 
[24]. 
  Several methods have been introduced to infer temporal 
progression of gene mutations from cross-sectional data 
[18], [19], [20], [25], [26], [27], [28]. Desper et al. [25], [26] 
proposed a tree model inference algorithm based on the 
thought of maximum-weight which relates cancer 
progression to measurement on gains and losses of 
chromosomal regions in tumor cells. Moritz et al. [27] 
presented a Bayesian network model to quantify cancer 
progression by an unobservable accumulation process 
which is separate from the observable mutations. 
However, these methods infer temporal ordering at the 
level of individual mutations or genes. The problem with 
these approaches is that cancers usually exhibit 
mutational heterogeneity, since clinically and 
histologically identical cancers often have few mutated 
genes in common. Therefore, Moritz et al. [18] presented a 
probabilistic graphical model to estimate temporal 
pathways during cancer progression from cross-sectional 
mutation data, and provided a quantitative and intuitive 
tumorigenesis model showing that genetic events may be 
related to the phenotypic progression at the pathway 
level, since somatic mutations, especially those oncogenic 
driver mutations, perturb all kinds of metabolic, signaling 
and regulatory pathways. Therefore, different individuals 
might hold driver mutations in different genes within the 
same pathway. Recently, many researches [1], [2], [3], [12], 
[13], [14], [15], [16], [23] have indicated that driver 
mutations in the same pathway tend to be mutually 
exclusive, that is, most patients have no more than one 
mutation within the same pathway. Therefore, Vandin et 
al. [20] introduced the exclusivity among mutations 
(genes) within the same pathway to infer cancer pathways 
and tumor progression from cross-sectional mutation 
data. They formulated the Pathway Linear Progression 
problem as an integer linear program. In the formulation, 
any partition has to satisfy two requirements: the 
exclusivity of mutations within each gene set, and the 
progression across the sets. Therefore, the Pathway Linear 
Progression Reconstruction problem is NP-hard to 
identify the best partition by simultaneously considering 
both exclusivity and progression.     
  To reduce the computational complexity and solve the 
NP-hard problem of the Pathway Linear Progression 
Model in an efficient approach, we now introduce a new 
network-based method to infer cancer progression at the 
pathway level from cross-sectional mutation data. During 
construction of a gene network, we introduce the 
definition of exclusive degree to describe how much 
exclusive between each pair of genes, and to take into 
account the coverage overlap, coverage and weight, we 
define weight degree to describe the ratio between weight 
and coverage. In the constructed gene networks, 
mutations of all genes in each complete subnetwork are 
approximately exclusive. Therefore, we just need to find a 
set of non-overlapping complete subnetworks which meet 
the linear progression between them. The specific steps of 
the approach are as follows. In the first step we filter the 
mutation matrix and obtain the critical genes which have 
been reported in the previous research or have a high 
frequency of recurrence. In the second step, a gene 
network is constructed by calculating the exclusive score 
between each pair of genes. In the network, each node is a 
gene and the edge between a pair of nodes will be created 
if the exclusive score between the pair of genes is greater 
than or equal to a threshold  𝜆 . In the third step, we 
identify all complete subnetworks and sort them from 
large to small according to their coverage degree. Then we 
use an orderly iterative method to find the driver 
pathways which meet the requirement for a linear 
progression between them.                                                                                                                                                                                                                                                                                                                                                                              
2 METHODS 
2.1 Exclusivity and progression 
Vandin et al. [20] introduced Pathways Linear Progression 
Model to infer cancer pathways and tumor progression 
with two criteria from cross-sectional somatic mutation 
data. The first one is “exclusivity” which means most 
patients have no more than one mutation in a pathway. 
The second one is “progression”   which means the 
patients with gene mutations in a pathway have certainly 
gene mutations in the previous pathway. Given a binary 
mutation matrix 𝑀  with 𝑚  rows (samples  𝑠1, 𝑠2, … , 𝑠𝑚 ) 
and 𝑛  columns (genes  𝑔1,  𝑔2, … , 𝑔𝑛 ), where 𝑀𝑖,𝑗 = 1  if 
𝑔𝑗is mutated in sample 𝑠𝑖, and 𝑀𝑖,𝑗 = 0 otherwise. For a 
gene 𝑔, the coverage Γ(𝑔) = {𝑖: 𝑀𝑖,𝑔 = 1} represents the set 
of patients in which gene 𝑔 is mutated (Fig. 1). Similarly, 
for a sub-matrix 𝐺  of size 𝑚 × 𝑘  in the mutation 
matrix 𝑀, the coverage is denoted as Γ(𝐺) =∪𝑔∈𝐺 Γ(𝑔). For 
any pair of 𝑔𝑗 , 𝑔𝑘 ∈ 𝐺, 𝑔𝑗 ≠ 𝑔𝑘 , if Γ(𝑔𝑗) ∩ Γ(𝑔𝑘) = ∅, 𝐺  is 
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mutually exclusive.  
Pathways Linear Progression Model (PLPM) [20]. A 
mutation matrix 𝑀 of size 𝑚 × 𝑛 satisfies the Pathways 
Linear Progression Model 𝑃𝐿𝑃𝑀(𝐾) with parameter 𝐾 >
1 , if there is a partition 𝑃 = {𝑃1, 𝑃2, … ,  𝑃𝐾}  of all the 
columns of 𝑀 into 𝐾 sets such that: 
1. For each row 𝑠𝑖  of 𝑀, if |{𝑔𝑗 ∈ 𝑃𝑘: 𝑀𝑖,𝑗 = 1}| ≤ 1, then 
among all the rows within one set 𝑃𝑘  are mutually 
exclusive, that is, for each pair of genes  𝑔𝑗1 , 𝑔𝑗2 ∈
𝑃𝑘 , 1 ≤ 𝑗1, 𝑗2 ≤ 𝑛  and   𝑗1 ≠ 𝑗2 , if  Γ(𝑔𝑗1) ∩ Γ(𝑔𝑗2) = ∅ , 
among all the rows within one set 𝑃𝑘 are mutually 
exclusive. 
2. For all 1 < 𝑘 ≤ 𝐾, if Γ(𝑃𝑘) ⊆ Γ(𝑃𝑘−1), then each row 𝑠𝑖  
of 𝑀 satisfies the progression on the sets  𝑃1, … , 𝑃𝐾 , 
that is, for all  1 < 𝑘 ≤ 𝐾 , if  |{𝑔𝑗 ∈ 𝑃𝑘: 𝑀𝑖,𝑗 = 1}| > 0 , 
then |{𝑔𝑗 ∈ 𝑃𝑘−1: 𝑀𝑖,𝑗 = 1}| > 0. 
 
Fig. 1. Pathways linear progression model [20]. (a) A linear 
progression model on gene sets creates a mutation matrix with 
mutually exclusive mutations within each gene set, and a progression 
of mutations across the gene sets; (b) In real dataset, errors that 
disrupt the exclusivity and the progression are present. 
For a sub-matrix 𝐺  of size  𝑚 × 𝑘  in the mutation 




.                (1) 
For a pair of genes 𝑔𝑗 , 𝑔𝑘 , their exclusive degree function is 
denoted as: 
𝐸𝐷(𝑔𝑗 , 𝑔𝑘) =
|Γ(𝑔𝑗)∪Γ(𝑔𝑘)|
|Γ(𝑔𝑗)|+|Γ(𝑔𝑘)|
.           (2) 
According to the above formula, 𝐸𝐷(𝐺) = 1 when 𝐺 is 
mutually exclusive. That is, each row of 𝐺  contains at 
most one mutation.  
For a sub-matrix 𝐺  of size  𝑚 × 𝑘  in the mutation 
matrix 𝑀, the coverage overlap [23] is denoted as: 
𝜔(𝐺) = ∑ |Γ(𝑔)|𝑔∈𝐺 − | Γ(𝐺)|.          (3) 
For a pair of genes  𝑔𝑗 , 𝑔𝑘 , their coverage overlap is 
denoted as: 
𝜔(𝑔𝑗 , 𝑔𝑘) = |Γ(𝑔𝑗)| + |Γ(𝑔𝑘)| − |Γ(𝑔𝑗) ∪ Γ(𝑔𝑘)|.  (4) 
Considering both the coverage overlap 𝜔(𝑔𝑗 , 𝑔𝑘) and the 
two coverages Γ(𝑔𝑗) and Γ(𝑔𝑘), the weight degree function 
is denoted as: 
     𝑊𝐷(𝑔𝑗 , 𝑔𝑘) = 1 −
|Γ(𝑔𝑗)∩Γ(𝑔𝑘)|
𝑚𝑖𝑛 {|Γ(𝑔𝑗)|,|Γ(𝑔𝑘)|}
.    (5) 
For a sub-matrix 𝐺  of size  𝑚 × 𝑘  in the mutation 
matrix 𝑀, the coverage degree function is denoted as:  
                   𝐶𝐷(𝐺) =
| Γ(𝐺)|
𝑚
.              (6) 
For a pair of genes 𝑔𝑗 , 𝑔𝑘 , their coverage degree function is 
denoted as: 
𝐶𝐷(𝑔𝑗 , 𝑔𝑘) =
|Γ(𝑔𝑗)∪Γ(𝑔𝑘)|
𝑚
.         (7) 
Note that 𝐶𝐷(𝐺) = 1, when 𝐺 is the complete coverage. 
That is, each row of 𝐺 contains at least one mutation. 
For two sub-matrices  𝑀𝑗 , 𝑀𝑘  with 𝐶𝐷(𝑀𝑗) > 𝐶𝐷(𝑀𝑘), the 
progression ratio of them is denoted as: 
𝑃𝑅(𝑀𝑗 , 𝑀𝑘) =
|Γ(𝑀𝑗)∩Γ(𝑀𝑘)|
|Γ(𝑀𝑘)|
.        (8) 
Note that 𝑃𝑅(𝑀𝑗 , 𝑀𝑘) = 1  when mutations of all genes 
in 𝑀𝑘 are a subset of mutations of all genes in 𝑀𝑗. 
2.2 The proposed NetInf method 
The proposed NetInf method consists of the following 
procedures and computational steps.  
2.2.1 Constructing a gene network based on 
approximate exclusivity 
Vandin et al. [20] introduced Pathway Linear Progression 
Model (PLPM) which was defined for an integer 𝐾 > 1 as 
an integer linear program problem of looking for 𝒫∗ =
𝑎𝑟𝑔𝑚𝑖𝑛𝑃∈𝒫(𝐾)𝑓(𝑀, 𝒫), and showed that the problem is an 
NP-hard problem. To solve it more efficiently, we 
construct a weighted gene network based on exclusive 
degree between each pair of genes to simplify the 
relationships between the genes and to significantly 
reduce the computational complexity. First, we calculate 
the exclusive degree between each pair of genes in a 
mutation matrix by using formula (2). Second, we 
construct a weighted gene network in which each node is 
a gene and the weight of an edge is the exclusive degree of 
the two connected genes. In the process of constructing a 
gene network, for each pair of genes   𝑔𝑗 , 𝑔𝑘 , 
if  𝐸𝐷(𝑔𝑗 , 𝑔𝑘) ≥ 𝜆  and   𝑊𝐷(𝑔𝑗 , 𝑔𝑘) ≥ 𝛾 , an edge will be 
created to link this pair of genes, otherwise, there is no an 
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edge between the pair of genes. The process is shown in Fig. 2. 
Fig. 2. An illustration of the steps in the process of inferring cancer progression at the pathway level. (a) A mutation matrix is created 
using somatic mutation data from multiple patients; (b) The exclusive degree between each pair of genes is calculated and a gene interaction 
network is constructed according to the exclusive degrees. If the exclusive degree between a pair of genes is greater than or equal to 𝜆, an edge is 
created between the two genes and the exclusive degree is represented as its weight; (c) All complete subnetworks are detected and sorted from 
large to small according to their coverage degree. 
2.2.2 Detecting pathways which meet the 
requirement for a linear progression 
In a gene network, according to the process of 
construction in the previous step, mutations of all genes in 
each complete subnetwork are approximately exclusive. 
Therefore, we need to find the non-overlapping complete 
subnetworks which meet the definition of PLPM. Firstly, 
we find all gene sets in which each gene set can constitute 
a complete subnetwork in the gene network. Secondly, we 
sort the gene sets found in the previous step from large to 
small according to their coverage degree and create a 
doubly-linked list. Finally, we identify gene sets which 
meet the linear progression from the doubly-linked list.  
  The step-by-step description of the algorithm for 
identifying gene sets which meet the linear progression 
starting from the first gene set 𝑀0 in the doubly-linked list 
is as follows. 
Step 1: Create a null doubly-linked list 𝑁, and set the step 
number  𝑠 = 0  for doubly-linked list  𝑀  and  𝑡 = 0  for 
doubly-linked list 𝑁.   
Step 2: Let 𝑁𝑡 = 𝑀𝑠.  
Step 3: If there is no intersection between genes in 𝑀𝑠+1 
and 𝑁, calculate progression ratio between 𝑀𝑠+1 and 𝑁𝑡 
using formula (8). Otherwise, 𝑠 = 𝑠 + 1 and continue Step 
3. 
Step 4: If   𝑃𝑅(𝑁𝑡, 𝑀𝑠+1) ≥ 𝛿,  𝑁𝑡+1 = 𝑀𝑠+1, 𝑡 = 𝑡 + 1  and 
𝑠 = 𝑠 + 1. Otherwise, 𝑠 = 𝑠 + 1 and return to Step 3. 
Step 5: If the number of genes in doubly-linked list  𝑁 is 
less than the number of all genes and there is no end of the 
doubly-linked list  𝑀, return to Step 3. Otherwise, go to 
Step 6. 
Step 6: If the number of genes in doubly-linked list  𝑁 is 
less than the total number of genes, delete node 𝑁𝑡 , 𝑡 = 𝑡 −
1, 𝑠 = 𝑠 + 1 and return Step 2. Otherwise, output the gene 
sets in doubly-linked list  𝑁 and end the process. 
  We can identify the gene sets in which mutations within 
each gene set are approximately exclusive and mutations 
across them meet the linear progression. 
2.3 Parameter settings 
In the NetInf method, a threshold 𝜆 is applied to decide 
whether there exists an edge between each pair of genes 
according to their exclusive degree. A threshold γ  is 
applied to describe the ratio between non-overlap 
(weight) and coverage. Another threshold 𝛿  is used to 
determine whether there exists a linear progression 
between two pathways. If  𝜆 = 1, γ = 1 and  𝛿 = 1, this is 
an ideal case for the gene sets to satisfy the Pathways 
Linear Progression Model. For a real mutation data, there 
always exist errors which disrupt the exclusivity or 
progression. Therefore,  𝜆, 𝛾 and 𝛿 are usually less than 
1. In the process of constructing a gene network, we set 
𝜆 = 0.95 as reported in [1]. In order to avoid the case 
where two connected genes have a high exclusive degree 
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but a low weight degree, we create formula (5) and 
analyze different weight degrees of two genes with the 
same coverage, coverage overlap and exclusive degree 
(Fig. 3).  
Although the coverage, coverage overlap and exclusive 
degree of the two genes 𝑔𝑗 , 𝑔𝑘 in the four cases in Fig. 3 
are the same, the two genes  in Fig. 3a&b are usually 
regarded as exclusive, while the two genes in Fig. 3c&d 
are not regarded as exclusive [1]. We obtain ideal results 
on simulated data and biological data when we attempt to 
set γ = 0.8 and 𝛿  as adjustable value, that is, Fig. 3b is 
regarded as a boundary instance. 
 
Fig. 3. Analysis of the weight degrees in two genes with the 
same coverage, coverage overlap and exclusive degree. The 
numbers in the figure stand for coverage in different cases. The 
coverage of the two genes in the four cases is |Γ(𝑔𝑗 , 𝑔𝑘)| = 95; the 
coverage overlap of the two genes in the four cases is 𝜔(𝑔𝑗 ,  𝑔𝑘) = 5; 
the exclusive degree of the two genes in the four cases 
is 𝐸𝐷(𝑔𝑗 , 𝑔𝑘) = 0.95. But the weight degrees are different in the four 
cases, (a) 𝑊𝐷(𝑔𝑗 , 𝑔𝑘) = 0.9; (b) 𝑊𝐷(𝑔𝑗 , 𝑔𝑘) = 0.8; (c) 𝑊𝐷(𝑔𝑗 , 𝑔𝑘) =
0.67; (d) 𝑊𝐷(𝑔𝑗 , 𝑔𝑘) = 0. 
In the experiment on simulated data, when noise 
probability p is set to be 0.001 and 𝛿 is set to be 0.95, we 
obtain exact results from 12 runs out of 20; when noise 
probability p is set to be 0.001 and 𝛿 is set to be 0.92, we 
obtain exact results from 20 runs; when noise probability 
p is set to be 0.05 and 𝛿 is set to be 0.9, we obtain the 
results from 6 runs out of 20; when noise probability p is 
set to be 0.05 and 𝛿 is set to be 0.85, we obtain the results 
from 18 runs out of 20. The results show when 𝛿 is set to 
be 0.95, we can obtain ideal results only if the progression 
model has very low noise; when 𝛿 is set to be 0.85, we 
can obtain ideal results even If noise probability p is 
relatively high. Given the close correlation between the 𝛿 
value and the noise level, we set an adjustable value 
of  0.85 ≤ 𝛿 ≤ 0.95 . Therefore, we set   𝜆 = 0.95, γ = 0.8 
and an adjustable value of 0.85 ≤ 𝛿 ≤ 0.95 which yield 
ideal results in conducting the experiments. 
3 RESULTS 
To assess the robustness of the proposed NetInf method, 
we apply it on simulated data with the addition of 
different levels of noise [20]. When executing the method 
on a conventional computer, NetInf can obtain ideal 
results. To verify the performance of NetInf, we apply it 
on three biological datasets (Table 1) and compare the 
results with ILP. The detailed comparison is elaborated 
below. 
3.1. Simulated data 
We perform a large number of experiments on simulated 
data with different levels of noise. We generate mutation 
data according to a progression model 𝒫 to which noise 
is added. First, we consider a progression model with 
𝑘 = 4, 𝑘 = 5  stages, each containing 𝑛 = 4, 𝑛 = 5 genes, 
respectively, and generate 20 mutation data with 𝑚 
samples, adding noise with different probabilities   𝑝 to 
the corresponding mutation data. We consider values of 
𝑚 = 50, 100, 200, 400, 600, 800, 1000  and  𝑝 = 0.001, 0.01,
0.05. For each combination  𝑚, 𝑝, we record the correct 
ratio which is the ratio between the number of genes 
belonging to corresponding sets and the total number of 
genes (Fig. 4). 
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Fig. 4. Correct ratio for different number of samples and different probabilities of noise addition. Correct ratio is shown on the graph on 𝑚 
samples, where the mutation matrix 𝑀 is based on a linear progression model with 𝑘 sets, each containing 𝑛 genes. Noise is added to the matrix 
𝑀 with a probability 𝑝. (a) Results for 𝑘 = 4, 𝑛 = 4 and different values of  𝑝 and 𝑚; (b) Results for 𝑘 = 5, 𝑛 = 5 and different values of   𝑝 and 𝑚. 
  As we can see, the correct ratio is very high when the 
number of samples increases and the probability of error 
decreases. In Fig. 4a, we can obtain absolutely right results 
when the number of samples is not less than 200 or the 
probability of error  𝑝 = 0.001. In fact, if the probability of 
error is not very high or the number of samples is not very 
small, we can get ideal results for 𝑘 = 4 and 𝑛 = 4. In Fig. 
4b, we can obtain absolutely right results when the 
number of samples is not less than 600 or the probability 
of error  𝑝 = 0.001. Actually, if the probability of error is 
less than 0.01 or the number of samples is more than 200, 
we can get ideal results for 𝑘 = 5 and 𝑛 = 5. These results 
show that data from the reasonable number of cancer 
samples can be used to infer the correct progression 
model. If the noise level is relatively high, the number of 
cancer patients is required to be large to infer the correct 
progression model. 
3.2 Real data 
To assess the performance of our NetInf on real biological 
data, we analyze three somatic mutation data from 
published cancer studies. In table 1, we present the 
information about number of genes, number of samples, 
maximum mutation frequency for all genes, average of 
mutation frequency for all genes and average mutation 
number of each sample. 
TABLE 1 
Biological Datasets Used in This Study 
Cancer type #Patient #Gene MMF AMF AMN 
CRC 1 94 8 78 29.9 2.52 
CRC 2 223 14 165 44.1 2.77 
GBM 290 27 90 17.7 1.65 
In the table, #Patient: number of patients; #Gene: number of genes; 
MMF: maximum mutation frequency for all genes; AMF: average of 
mutation frequency for all genes; AMN: average mutation number of 
each sample; CRC 1: Colorectal cancer data reported in [29]; CRC 2: 
Colorectal cancer data from TCGA [5]; GBM: glioblastoma multiforme 
data from TCGA [5].  
3.2.1 SCIENCEMAG: Colorectal cancer data 
We first apply NetInf to colorectal cancer data reported in 
[29]. The data contains 94 samples and eight genes for 
which mutation frequency is over 5%. They are TP53, 
KRAS, EVC2, APC, EPHA3, FBXW7, PIK3CA and 
TCF7L2. The progression model inferred with the use of 
the ILP method is shown in Fig. 5a, and it shares close 
similarities with the model inferred with the use of the 
proposed NetInf method (Fig. 5b). 
Fig. 5. Progression models built with the use of colorectal 
cancer data. (a) Results obtained by applying the ILP method [20]; 
(b) Results obtained by applying the proposed here NetInf method. 
Dashed oval boxes show the differences between the results of ILP 
and NetInf. Dashed rectangular boxes in Fig. 5b&6b show the same 
order of the six genes appearing in the two colorectal cancer datasets. 
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  The only difference between the two progression 
models is that mutations in EVC2 occur early in the 
progression model inferred by NetInf, while TCF7L2 
mutations appear later. These results seem to be 
reasonable because EVC2 mutations have been reported 
to be precursor node of TCF7L2 in colorectal cancer [18]. 
  Interestingly, gene set (APC, EPHA3, EVC2) in our 
results has the same coverage degree but larger exclusive 
degree (90.9%) than gene set (APC, EPHA3, TCF7L2) in 
[20], showing that the gene set (APC, EPHA3, EVC2) is 
more likely in the same functional pathway [30]. APC and 
EPHA3 have stable co-expression together with a 
cytoplasmic form of BirA for efficient biotinylation of 
AP-tagged EPHA3 C-terminus [31]. However, gene set 
(APC, EPHA3, EVC2) shows no significant enrichment 
using the DAVID functional annotation tool [32]. Gene set 
(PIK3CA, TP53, TCF7L2) with p-value=1.1E-4 shows 
significant enrichment, and they are the core members of 
the pathways in cancer and Wnt/Notch signaling 
pathways. The functions of PIK3CA and TP53 are related 
to age at disease onset [33]. The details, including 
coverage degree, exclusive degree and p-value of each 
pathway, are presented in Table 2. We want to find the 
gene sets whose coverage degree and exclusive degree are 
simultaneously large, but it is necessary to point out that 
exclusive degree increases at the expense of declining 
coverage degree, and vice versa [1]. The analyses show 
that the NetInf method proposed here obtains a more 
accurate tumor progression model of colorectal cancer 
than the ILP method. 
TABLE 2 
Results of ILP and NetInf Methods for Colorectal Cancer Data 
Gene 
sets 
Results of ILP Results of NetInf 
CD ED P CD ED P 
Set 1 85.1% 88.8% 2.1E-2 85.1% 90.9% N/A 
Set 2 78.7% 90.2% 9.7E-3 78.7% 88.1% 1.1E-4 
Set 3 62.8% 100% N/A 62.8% 100% N/A 
Set 4 8.5% 100% N/A 8.5% 100% N/A 
In the table, CD: Coverage degree; ED: Exclusive degree; P: p-value, 
which is obtained using the DAVID functional annotation tool 
(“http://david.abcc.ncifcrf.gov/summary.jsp”). The contents of Set (i) 
are corresponding to the pathways displayed in Fig. 5 respectively. 
N/A represents no significant enrichment. 
3.2.2 TCGA: Colorectal cancer data 
We download colorectal mutation data from TCGA study 
and analyze 223 samples on this type of cancer. We choose 
14 genes identified as recurrent mutation by MutSigCV 
[34]. The progression model inferred with the use of the 
ILP is shown in Fig. 6a, and it shares some similarities 
with the one inferred with the use of the NetInf (Fig. 6b). 
The details, including coverage degree, exclusive degree 
and p-value of each pathway, are presented in Table 3. 
Fig. 6. Progression models built with the use of colorectal 
cancer data from TCGA. (a) The results from the ILP method [20]; 
(b) The results from the proposed here NetInf method. 
  In the first stage of the progression, mutations in APC 
always occur early in tumor progression [20]. ELF3 is a 
member of the E-twenty-six family of transcription factors 
and it drives 𝛽 -catenin transactivation [35]. In the 
hypermutated tumors, APC and ACVR2A are frequent 
targets of mutation, along with most BRAF mutations, and 
they commonly target specific genes MIR192, MIR215 and 
MAPK8 [36]. The gene set is altered in 76.2% with large 
exclusive degree at 92.4%. In the second stage of the 
progression, TP53 binds to the PIK3CA promoter and 
inhibits its activity. Up-regulation of PIK3CA and 
inactivation of TP53 contribute to the pathophysiology of 
many human cancers [1]. SiRNA-mediated reduction in 
TCF7L2 activity results in increased expression of TP53, 
and results in increased p53 protein activity and an 
elevated expression of the p53 target gene Tp53inp1 [37]. 
PIK3CA mutations are associated with over-expression of 
TCF7L2 involved in the Wnt signaling pathway [38]. The 
same gene set has been identified in the first experiment, 
and PIK3CA, TP53 and TCF7L2 are core members of the 
pathways in cancer and Wnt/Notch signaling pathways. 
In the non-hypermutated tumors, the three genes are 
usually regarded as most frequently mutated genes [36]. 
The gene set is altered in 78.7% with p-value= 1.1E-4. In 
the third stage of the progression, the same results have 
been identified in [20] and BRAF, KRAS and NRAS are the 
core members of the RAS/RAF/MAPK signaling 
pathways. The three mutated genes usually have 
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oncogenic codon 12 and 13 or codon 61 mutations [36]. 
The gene set is altered in 59.6% with large exclusive 
degree at 95.7% and p-value=2.7E-5. In the fourth stage of 
the progression, SMAD2 and SMAD4 are the core 
members of the WNT signaling pathway. SMAD4 
interacts with SMAD2, and SMAD2 interacts with SOX9 
[20]. Mutations in FBXW7 have been reported to appear 
after KRAS mutations in [18], [20].  
TABLE 3 
Results Obtained with the Use of the ILP and NetInf Methods for 
Colorectal Cancer Data from TCGA 
Gene 
sets 
Results of ILP Results of NetInf 
CD ED P CD ED P 
Set 1 80.7% 87.8% N/A 76.2% 92.4% N/A 
Set 2 75.3% 78.5% 6.4E-2 69.1% 87.0% 1.1E-4 
Set 3 59.6% 95.7% 2.7E-5 59.6% 95.7% 2.7E-5 
Set 4 21.5% 94.1% 1.4E-2 34.5% 84.6% 2.9E-2 
Set 5 3.6% 100% N/A 11.7% 100% N/A 
The contents of Set (i) are corresponding to the pathways displayed in 
Fig. 6 respectively. 
Interestingly, six genes APC, TP53, PIK3CA, TCF7L2, 
KRAS and FBXW7 in the dataset also appear in the first 
experiment. Moreover, we find that these genes have the 
same assignments in different stages of the two 
progression models, that is, mutations in APC occur in the 
first stage, mutations in TP53, PIK3CA and TCF7L2 occur 
in the second stage, mutations in KRAS occur in the third 
stage and mutations in FBXW7 occur in the fourth stage, 
and we obtain the same gene set (TP53, PIK3CA and 
TCF7L2) located in the second stage in the two 
progression models (Fig. 5b&6b). From the results, we can 
find the exclusive degree of the gene sets in NetInf is 
slightly higher than that of gene sets in ILP, and p-value of 
the gene sets in NetInf is slightly smaller than that of gene 
sets in ILP, so the gene sets in NetInf indicate more 
significant enrichment than that in ILP. The analyses show 
that the NetInf method proposed here obtains a more 
accurate tumor progression model of colorectal cancer 
based on the used data than the ILP method. 
 
Fig. 7. Progression models built with the use of glioblastoma 
multiforme data from TCGA [39]. Dashed boxes identify genes in 
the same signaling pathway, with different colors used to denote 
different signaling pathways. 
3.2.3 TCGA: Glioblastoma Multiforme data 
We download glioblastoma multiforme data from the 
TCGA study and analyze 290 samples of this cancer type. 
We restrict the analysis to the 27 genes reported in [39] as 
a part of pathway alterations in GBM. The progression 
model inferred with NetInf is shown in Fig. 7, and the 
details, including coverage degree, exclusive degree and 
p-value of each pathway, are shown in Table 4. 
TABLE 4 
Results Obtained with the Use of the ILP and NetInf Methods for 
Glioblastoma Multiforme Cancer Data from TCGA  
Gene sets CD ED P 
Set 1 61.0% 76.3% 9.8E-11 
Set 2 43.8% 93.4% 1.2E-8 
Set 3 29.7% 97.7% 4.5E-4 
Set 4 7.50% 100% 3.6E-2 
Set 5 0.30% 100% N/A 
The contents of Set (i) are corresponding to the pathways displayed in 
Fig. 7 respectively. 
  In the first stage of the progression, PIK3CA, PIK3CG, 
PIK3R1, PIK3R2, NF1 and BRAF are the core members of 
the RAF/RAS/PI3K signaling pathways. The gene set is 
altered in 61.0% with p-value=9.8E-11. In the second stage 
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of the progression, PIK3CB and PTEN are the members of 
the RAF/RAS/PI3K signaling pathways, and CDKN2A, 
CDK4 and CDK6 are the core members of the RB signaling 
pathway. CDKN2A inhibits CDK4, CDK4 inhibits p27, 
and p27 inhibits CDK6 in the RB signaling pathway. The 
gene set is altered in 43.8% with large exclusive degree at 
93.4% and p-value=1.2E-8. In the third stage of the 
progression, TP53, MDM2 and MDM4 are the core 
members of the p53 signaling pathway. MDM4 interacts 
with MDM2, MDM4 and MDM2 inhibit TP53, and TP53 
activates MDM2 in the p53 signaling pathway. The gene 
set is altered in 29.7% with large exclusive degree at 97.7% 
and p-value=4.5E-4. For the first three sets in the 
progression model, most genes in one set belong to the 
same known signaling pathway. The analyses show that 
the NetInf method proposed here identifies pathway 
relations among genes in the different progression stages 
and obtains an ideal cancer progression model based on 
the used data. 
4 DISCUSSION AND CONCLUSIONS  
Inference of cancer progression at the pathway level is an 
essential problem in computational biology. In this study, 
we use a progression model in which mutations within 
each gene set (pathway) are approximately exclusive, and 
they follow a linear progression at the pathway level. The 
problem of reconstructing the best progression model has 
been proved to be NP-hard [20], so we introduce a novel 
method called NetInf for automatic inference of cancer 
progression at the pathway level from cross-sectional 
mutation data without any prior biological knowledge. In 
this algorithm, the critical genes are firstly determined 
from mutation matrix by meeting a certain frequency of 
recurrence requirement or being reported in the previous 
research. Secondly, a gene network is constructed 
according to high exclusivity of mutations between each 
pair of genes to solve the problem of high complexity that 
the previous methods encounter. Thirdly, all the complete 
subnetworks in the gene network are identified and sorted 
from large to small according to their coverage degree, 
and then an orderly iterative method is used to find the 
pathways which meet the linear progression between 
them. The results show that integrative analysis of 
cross-sectional mutation data has the potential to identify 
gene sets which are closely related to cancer phenotypes 
in the process of cancer progression. Moreover, our 
algorithm makes it possible to find the function-related 
oncogene sets at different stages of cancer progression.  
  Comparing with the previous algorithms of inferring 
cancer progression, our algorithm is beneficial in the 
following three aspects. First, complexity of the solution is 
reduced by constructing gene networks according to high 
exclusivity of mutations between each pair of genes. 
Second, our algorithm does not need to assign the number 
of pathways in the progression model. Third, our 
algorithm infers cancer progression at the level of 
pathways rather than individual mutations or genes. It is 
necessary to note that this algorithm does not use gene 
expression data, known pathways, gene interaction data 
and other biological knowledge. The method may provide 
a supplement to the analyses of cancer data and it will be 
helpful in producing hypotheses which will drive some 
specific biological experiments and increase 
understanding for cancer progression [1], [40]. Further 
research is anticipated for the development of new 
machine learning techniques specific for this task [41]. We 
also plan to analyze the cancer progression models as 
binary temporal sequences modeled and visualized with 
the use of spiking neural networks, where a mutation of a 
gene can be represented as a spike at a certain time of the 
progression [42]. 
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